Clinical trials: Differentiated Thyroid Carcinoma
Melanoma, Glioma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors.
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT05538130
- Testing
- PF-07799544, PF-07799933
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 148 people
- Sponsor
- Pfizer
Thyroid
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
This pilot clinical trial studies how will metformin hydrochloride works in mitigating the side effects of radioactive iodine treatment in patients with differentiated thyroid cancer.
- Trial name
- NCT03109847
- Testing
- Metformin Hydrochloride, Radioactive Iodine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Thyroid Cancer
Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer
To explore the efficacy and safety of selective coverage radiotherapy in poorly differentiated and anaplastic thyroid cancer
- Trial name
- NCT07777536
- Testing
- Selective coverage radiotherapy, comprehensive coverage radiotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fudan University
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
This phase II trial studies how well lenvatinib works when given together with standard of care iodine I-131 in treating patients with radioactive iodine-sensitive differentiated thyroid cancer.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT03506048
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Emory University
Ovarian Insufficiency, Radiation Exposure
Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer
Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated.
- Trial name
- NCT04396158
- Testing
- radioactive iodine
- Volunteers
- 38 people
- Sponsor
- Assiut University
Thyroid Cancer
Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)
This research study is to compare the radiopharmacokinetics of I-124 to the radiopharmacokinetics of I-131 in patients who have well-differentiated thyroid cancer after recombinant human thyroid-stimulating hormone (rhTSH)…
- Trial name
- NCT00926978
- Testing
- Radioactive Iodine 124
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Medstar Health Research Institute
Differentiated Thyroid Cancer
Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer
Distant metastases is the leading cause of differentiated thyroid cancer-related death. Radioactive iodine (RAI) treatment is the most effective therapy for RAI-avid metastatic differentiated thyroid cancer (DTC).
- Trial name
- NCT04880798
- Testing
- 124I PET/CT
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Differentiated Thyroid Cancer
Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)
This is a single-centre open label phase II study evaluating the effect of lenvatinib treatment for restoring radioiodine uptake and retention in radioiodine-refractory (RAI-R) thyroid cancer to warrant I-131 therapy.
- Trial name
- RESET (NCT04858867)
- Testing
- rhTSH-stimulated I-124 dosimetry, Intra-therapeutic I-131 dosimetry
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Leiden University Medical Center
Differentiated Thyroid Cancer
Recurrence in Patients With Differentiated Thyroid Cancer
The aim of this study is to assess the recurrence-free survival (RFS) rate and recurrence-related factors, especially the relationship between RFS and RAI dose, in patients who received RAI after thyroidectomy.
- Trial name
- NCT06154863
- Testing
- RAI
- Volunteers
- 100 people
- Sponsor
- Assiut University
Renal Cell Carcinoma, Hepatocellular Carcinoma
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of…
- Conditions
- Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma
- Trial name
- NCT03776123
- Where
- 47 sites in South Korea
- Volunteers
- 347 people
- Sponsor
- Ipsen
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
This phase II trial evaluates Tunlametinib (MEK inhibitor) ± PD-1 in NRAS-mutant advanced thyroid cancer. Key Objectives: Assess efficacy (ORR by RECIST v1.1) Evaluate safety profiles Study Design: Single-arm, single-center 4…
- Trial name
- NCT06970353
- Testing
- Tunlametinib, Tunlametinib+PD-1 mAb
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well bortezomib works in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00104871
- Testing
- Bortezomib
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer.
- Trial name
- NCT06007924
- Testing
- Avutometinib, Defactinib
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Nodule
Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.
According to the grades of echogenicity to evulated thyroid nodules is a subjective process and is thus influenced by the observer's judgement.
- Trial name
- NCT03700762
- Testing
- ultrasound gray-scale ratio
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Hangzhou
Differentiated Thyroid Cancer
rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)
This study was conducted in patients with differentiated thyroid cancer who had undergone total/near-total thyroidectomy. After surgery patients were randomized to one of two methods of performing thyroid remnant ablation.
- Trial name
- NCT04964284
- Testing
- rhTSH, Radioiodine (131I)
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Differentiated Thyroid Cancer
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.
- Trial name
- NCT01263951
- Testing
- Everolimus, Sorafenib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Thomas Jefferson University
Thyroid Cancer
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
Prospective randomized open phase III non-inferiority trial in cT1bT2N0 papillary thyroid carcinoma comparing: total thyroidectomy alone (experimental group) versus total thyroidectomy + Prophylactic Neck Dissection PND…
- Trial name
- ESTIMABL3 (NCT03570021)
- Testing
- total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection, total thyroidectomy alone without neck dissection
- Where
- 21 sites in France, Guadeloupe and 1 more
- Volunteers
- 352 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Differentiated Thyroid Cancer
PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer
Description of the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.
- Trial name
- NCT03191643
- Volunteers
- 16 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Thyroid Neoplasms
Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients
The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management…
- Trial name
- NCT06853925
- Testing
- Radioactive Iodine Support (RAI Support), Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Georgetown University
Thyroid Neoplasms, Thyroid Cancer
Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia
The standard surgical treatment for highly differentiated papillary thyroid cancer > 10 mm according to recent national and international guidelines, is total thyroidectomy and central lymphnode clearance, and for patients with…
- Trial name
- SNTC (NCT01089335)
- Testing
- Histological investigation of the SN
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Skane